

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
1255 daily bars · split adjusted
Current price $46.49
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Daily · Wilder smoothing
| Apr 20, 26 |
| Barclays |
| upgrade |
| Underweight |
| Equal Weight |
| Dec 16, 25 | B of A Securities | upgrade | Neutral | Buy |
| Jun 3, 25 | Jefferies | upgrade | Hold | Buy |
| Mar 27, 25 | B of A Securities | downgrade | Neutral | Underperform |
| Jan 3, 25 | Exane BNP Paribas | upgrade | Neutral | Outperform |
| Apr 23, 24 | Citigroup | downgrade | Buy | Neutral |
| Mar 8, 24 | Morgan Stanley | upgrade | Equal Weight | Overweight |
| Dec 5, 23 | B of A Securities | downgrade | Buy | Neutral |
| Oct 16, 23 | RBC Capital | upgrade | Sector Perform | Outperform |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.75 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 27.02 | Oscillator | Neutral |
| Williams %R (14) | -87.18 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.00 (Hist 0.09) | Oscillator | Buy |
| Average Directional Index (14) | 25.05 (+DI 26.0 / -DI 39.7) | Trend | Strong Sell |
| EMA 20 | 48.01 | MA | Strong Sell |
| SMA 20 | 47.69 | MA | Sell |
| EMA 50 | 49.57 | MA | Strong Sell |
| SMA 50 | 50.84 | MA | Strong Sell |
| SMA 200 | 47.08 | MA | Sell |
Stock news · updated daily
Rentokil Initial PLC (LSE:RTO) has had its price target raised by UBS after third-quarter trading showed better-than-expected stability in its key North American pest control business. The broker reiterated its 'buy' rating and increased its target to 390p from 370p, compared with a share price of 342p.
Total Revenue: $1.48 billion, up 3.5% year over year.HOKA Revenue: Up 7% year over year; wholesale up 9% to $444 million, DTC up 4% to $234 million.UGG Revenue:
Total Revenue: Grew 16% year-over-year to $4.9 billion, a quarterly record.Rental Revenue: Increased 18% to $4.3 billion, a quarterly record.Fleet Productivity:
A UBS portfolio manager sees three technology waves pushing stocks far beyond Wall Street's consensus, but his bullish case runs straight through two more Fed rate hikes that most investors are not pricing in.
UBS (UBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Grid PLC (LSE:NG.), the energy network operator, is expected to report a record first-half operating profit, but UBS has maintained its 'sell' rating ahead of results on November 5.
UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.
TD Waterhouse Canada Inc. bought a new stake in shares of UBS Group AG (NYSE: UBS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 231,239 shares of the bank's stock, valued at approximately $10,943,000. Other institutional investors and hedge funds have also
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.90 | 0.87 | Miss -3.3% | $13.35B |
| Apr 29, 2026 | 0.85 | 0.94 | Beat 10.6% | $13.64B |
| Feb 4, 2026 | 0.54 | 0.37 | Miss -31.7% | $12.20B |
| Oct 29, 2025 | 0.49 | 0.76 | Beat 55.9% | $12.20B |
| Jul 30, 2025 | 0.70 | 0.72 | Beat 2.9% | $11.55B |
| Apr 30, 2025 | 0.42 | 0.51 | Beat 21.4% | $11.90B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 11-K/A | Oct 6, 2026 | 2026-10-06 13:59:53 | View |
| 11-K/A | Oct 6, 2026 | 2026-10-06 13:33:10 | View |
| N-PX | Aug 28, 2026 | 2026-08-28 06:08:11 | View |
| 6-K | Aug 14, 2026 | 2026-08-14 07:37:55 | View |
| 13F-HR | Aug 13, 2026 | 2026-08-13 09:41:40 | View |
| SC 13G | Aug 5, 2026 | 2026-08-05 11:20:05 | View |
| SC 13G | Aug 5, 2026 | 2026-08-05 10:54:17 | View |
| SC 13G | Aug 4, 2026 | 2026-08-04 17:32:57 | View |
| SC 13G | Aug 4, 2026 | 2026-08-04 17:05:47 | View |
| SC 13G/A | Aug 3, 2026 | 2026-08-03 16:28:29 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | UBS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 15.6x | 11.6x · sector 20.4x | Discount |
| Forward P/E (FY26E) | 12.8x | EPS est. 3.62 | Discount |
| Price / Book | 1.6x | 1.2x | Elevated |
| Price / Sales | 2.3x | 1.7x | Elevated |
| EV / EBITDA | 20.2x | 14.4x | Elevated |
| Return on equity | 10.3% | — | Healthy |
| Gross margin | 79.5% | 70.1% | In line |
| Debt / Equity | 4.21 | 4.06 | Levered |
| Piotroski / Altman Z | 7/9 | Z -0.27 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure